PDCD1 and hereditary clear cell renal cell carcinoma: At present, the immune checkpoint inhibitors used to treat advanced renal cell carcinoma, such as Keytruda and Opdivo, can enhance the immune response against renal cell carcinoma by blocking PD-1.